NDAORALTABLET
Approved
Nov 1950
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HETRAZAN (diethylcarbamazine citrate) is an oral small-molecule antiparasitic agent approved in 1950 for treating filarial infections and certain parasitic diseases. It works by paralyzing and killing microfilariae and adult worms, making it a foundational treatment in tropical medicine and neglected tropical disease programs.
LOE Approaching
Product is in advanced maturity stage with moderate competitive pressure (30%); team sizes are likely smaller and focused on cost optimization and market access in emerging markets.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Roles on HETRAZAN are primarily in market access, regulatory maintenance, and global health initiatives rather than commercial growth or innovation. Career progression here emphasizes emerging market expertise, pharmacovigilance, and partnerships with WHO and NGOs.
Regulatory Affairs ManagerGlobal Health Access Manager
Worked on HETRAZAN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.